Pharma, Healthcare Q4 Results Preview - Domestic Business Marred By Weak Seasonality: Yes Securities

Yes Securities Report

Q4 typically sees weakness in domestic acute business on account of low seasonality. U.S. business is expected to exhibit moderate growth as operating environment remains presumably benign.

India business for most companies especially chronic focused ones would grow 9-11% YoY while acute heavy ones might have to endure mid-single digit growth.

Large companies like Lupin, Dr. Reddy’s Laboratories would continue to benefit from product specific boost like Spiriva and Revlimid (some seasonal weakness not ruled out) while smaller ones would have to rely on existing business to drive growth in U.S.

Diagnostic players would see broad volume range with Vijaya Diagnostic Ltd. again leading the pack. We reckon Torrent Pharma, Lupin and Ajanta Pharma could report better than expected numbers while Alkem Labs and JB Chemicals likely to disappoint extant consensus expectations.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.